Sunday, Oct 04th

Last update07:13:17 PM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.


Most Recent Related Stories...

Doctors Without Borders leaves Kunduz after 'inexcusable' air strike

DWBInternational medical charity Doctors Without Borders (MSF) said Sunday it has withdrawn staff from the embattled...

Federal health program for Sept. 11 responders set to expire

First responders health coverageA law that provides medical monitoring and treatment for Sept. 11 first responders expires at midnight...

England, Wales ban smoking in cars with children inside

Smoking in car with childrenSmokers who light up in vehicles with children inside will face fines in England and Wales...

Medicare defrauded of $54M through ambulance transport services

Medicare ambulance fraudMedicare paid about $54 million in possibly fraudulent ambulance transport services in the first half of...
America's # 1 Enemy
Tee Shirt
& Help Support!
TVNL Tee Shirt
Conserve our Planet
& Help Support!
Get your 9/11 & Media
Deception Dollars
& Help Support!
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!